There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vaxxinity Inc (VAXX – Research Report), Amgen (AMGN – Research Report) and LivaNova (LIVN – Research Report) with bullish sentiments.
Vaxxinity Inc (VAXX)
In a report issued on December 2, Roger Song from Jefferies maintained a Buy rating on Vaxxinity Inc, with a price target of $15.00. The company’s shares closed last Friday at $2.04, close to its 52-week low of $1.26.
According to TipRanks.com, Song has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vaxxinity Inc with a $15.00 average price target.
See the top stocks recommended by analysts >>
Amgen (AMGN)
In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Amgen, with a price target of $325.00. The company’s shares closed last Friday at $285.51, close to its 52-week high of $296.67.
According to TipRanks.com, Yee is a 2-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Amgen with a $259.57 average price target.
LivaNova (LIVN)
In a report released yesterday, Matthew Taylor from Jefferies reiterated a Buy rating on LivaNova, with a price target of $80.00. The company’s shares closed last Friday at $55.69.
According to TipRanks.com, Taylor is a 5-star analyst with an average return of
Currently, the analyst consensus on LivaNova is a Strong Buy with an average price target of $74.80, which is a 35.1% upside from current levels. In a report issued on November 23, Goldman Sachs also maintained a Buy rating on the stock with a $63.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VAXX:
- Vaxxinity announces Phase 3 COVID-19 booster data for UB-612
- Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612
- Vaxxinity to hold analyst and research and development day
- Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Vaxxinity to Present at Upcoming Investor Conferences in November
